Sign In
Buy WXXWY
$8.21
-0.700 (-7.86%)
At Close: Jun 03, 2026
Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
06:47am, Tuesday, 29'th Apr 2025
Contributing to United Nations Sustainable Development Goals Enhancing transparency and effectiveness for corporate governance Empowering employees and delivering positive impact to communities Accele
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
04:30am, Tuesday, 22'nd Apr 2025
Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI , April 22, 20
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
02:30am, Friday, 18'th Apr 2025
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors- Proprietary process innovation reduces protei
WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards
09:07am, Monday, 14'th Apr 2025
SHANGHAI , April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
06:30am, Tuesday, 25'th Mar 2025
Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
08:30pm, Sunday, 23'rd Mar 2025
SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
08:30pm, Thursday, 20'th Mar 2025
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and s
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
07:30pm, Monday, 03'rd Mar 2025
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system.
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
11:30pm, Wednesday, 26'th Feb 2025
WUXI, China , Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
04:00am, Tuesday, 18'th Feb 2025
Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation fo
Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for
WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)
05:18pm, Tuesday, 21'st Jan 2025
My rating upgrade for WuXi Biologics to a Buy has taken into consideration its latest corporate move and business disclosures. The sale of its European manufacturing facility will throw up margin impr
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
07:00pm, Monday, 06'th Jan 2025
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and i
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
07:00pm, Monday, 06'th Jan 2025
SHANGHAI and SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a
China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
07:50am, Monday, 06'th Jan 2025
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million.
